Teachers Advisors’s Galectin Therapeutics GALT Stock Holding History

Teachers Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-29,899	Closed	-$100K	–	3098
2015 Q1	$100K	Buy	29,899 +4,438	+17%	+$15.9K	﹤0.01%	3024
2014 Q4	$88K	Hold	25,461	–	–	﹤0.01%	3062
2014 Q3	$128K	Hold	25,461	–	–	﹤0.01%	3010
2014 Q2	$352K	Buy	+25,461	New	+$317K	﹤0.01%	2645

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Teachers Advisors's GALT Position: Q2 2015 in Review

Teachers Advisors sold out of Galectin Therapeutics (GALT) in Q2 2015, closing a stake of 29,899 shares — an estimated $100K sold.

Teachers Advisors first reported a position in GALT in Q2 2014 and held it in 4 quarters. The position peaked at $352K in Q2 2014. 58 funds tracked by Wall St. Rank hold GALT as of Q2 2015.

Teachers Advisors reported no remaining Galectin Therapeutics position as of Q2 2015 after selling out during the quarter.
Teachers Advisors sold 29,899 Galectin Therapeutics shares in Q2 2015, an estimated $100K.
Teachers Advisors first reported a position in Galectin Therapeutics in Q2 2014 and held it in 4 quarters.
Teachers Advisors's Galectin Therapeutics position peaked at $352K in Q2 2014.
58 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2015.

Based on Teachers Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.